Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for Mild COVID-19
NCT04340544Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine with Placebo (2 arms). Primary endpoint: Time to resolution of clinical signs and symptoms at 28 days. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04340544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340544.